| Management of glioblastoma: State of the art and future directions AC Tan, DM Ashley, GY López, M Malinzak, HS Friedman, M Khasraw CA: a cancer journal for clinicians 70 (4), 299-312, 2020 | 1373 | 2020 |
| High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, M Kok, ... Annals of Oncology 32 (5), 661-672, 2021 | 708 | 2021 |
| Longitudinal molecular trajectories of diffuse glioma in adults FP Barthel, KC Johnson, FS Varn, AD Moskalik, G Tanner, E Kocakavuk, ... Nature 576 (7785), 112-120, 2019 | 412 | 2019 |
| Tumor mutational burden as a predictor of immunotherapy response: is more always better? JH Strickler, BA Hanks, M Khasraw Clinical Cancer Research 27 (5), 1236-1241, 2021 | 291 | 2021 |
| Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance DLH Chan, N Pavlakis, GP Schembri, EJ Bernard, E Hsiao, A Hayes, ... Theranostics 7 (5), 1149, 2017 | 248 | 2017 |
| Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized … A Omuro, AA Brandes, AF Carpentier, A Idbaih, DA Reardon, ... Neuro-oncology 25 (1), 123-134, 2023 | 230 | 2023 |
| Epirubicin: is it like doxorubicin in breast cancer? A clinical review M Khasraw, R Bell, C Dang The Breast 21 (2), 142-149, 2012 | 223 | 2012 |
| Glioma progression is shaped by genetic evolution and microenvironment interactions FS Varn, KC Johnson, J Martinek, JT Huse, MLP Nasrallah, P Wesseling, ... Cell 185 (12), 2184-2199. e16, 2022 | 211 | 2022 |
| Adaptive global innovative learning environment for glioblastoma: GBM AGILE BM Alexander, S Ba, MS Berger, DA Berry, WK Cavenee, SM Chang, ... Clinical Cancer Research 24 (4), 737-743, 2018 | 179 | 2018 |
| Antiangiogenic therapy for high‐grade glioma M Khasraw, MS Ameratunga, R Grant, H Wheeler, N Pavlakis Cochrane Database of Systematic Reviews, 2014 | 161 | 2014 |
| Advances in the treatment of malignant gliomas M Khasraw, AB Lassman Current oncology reports 12, 26-33, 2010 | 161 | 2010 |
| Anti‐angiogenic therapy for high‐grade glioma M Ameratunga, N Pavlakis, H Wheeler, R Grant, J Simes, M Khasraw Cochrane Database of Systematic Reviews, 2018 | 147 | 2018 |
| Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies ST Garber, Y Hashimoto, SP Weathers, J Xiu, Z Gatalica, RGW Verhaak, ... Neuro-oncology 18 (10), 1357-1366, 2016 | 136 | 2016 |
| Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium Neuro-oncology 20 (7), 873-884, 2018 | 131 | 2018 |
| MYCN amplification drives an aggressive form of spinal ependymoma DR Ghasemi, M Sill, K Okonechnikov, A Korshunov, S Yip, PW Schutz, ... Acta neuropathologica 138, 1075-1089, 2019 | 127 | 2019 |
| Machine-learning prediction of cancer survival: a retrospective study using electronic administrative records and a cancer registry S Gupta, T Tran, W Luo, D Phung, RL Kennedy, A Broad, D Campbell, ... BMJ open 4 (3), e004007, 2014 | 115 | 2014 |
| Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma A Omuro, TA Chan, LE Abrey, M Khasraw, AS Reiner, TJ Kaley, ... Neuro-oncology 15 (2), 242-250, 2013 | 113 | 2013 |
| EpCAM aptamer-mediated survivin silencing sensitized cancer stem cells to doxorubicin in a breast cancer model T Wang, MP Gantier, D Xiang, AG Bean, M Bruce, SF Zhou, M Khasraw, ... Theranostics 5 (12), 1456, 2015 | 108 | 2015 |
| PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma? M Khasraw, DA Reardon, M Weller, JH Sampson Clinical Cancer Research 26 (20), 5287-5296, 2020 | 104 | 2020 |
| Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy M Gromeier, MC Brown, G Zhang, X Lin, Y Chen, Z Wei, N Beaubier, ... Nature communications 12 (1), 352, 2021 | 99 | 2021 |
Stephen ClarkeProfessor of Medicine, University of Sydney and Medical Oncologist, RNSH and Genesis Care在 sydney.edu.au 的电子邮件经过验证
